FR2736638B1 - Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent - Google Patents

Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent

Info

Publication number
FR2736638B1
FR2736638B1 FR9508423A FR9508423A FR2736638B1 FR 2736638 B1 FR2736638 B1 FR 2736638B1 FR 9508423 A FR9508423 A FR 9508423A FR 9508423 A FR9508423 A FR 9508423A FR 2736638 B1 FR2736638 B1 FR 2736638B1
Authority
FR
France
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
transferase inhibitors
farnesyl transferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9508423A
Other languages
English (en)
Other versions
FR2736638A1 (fr
Inventor
Bernard Baudoin
Christopher Burns
Alain Commercon
Alain Lebrun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to FR9508423A priority Critical patent/FR2736638B1/fr
Priority to ZA965750A priority patent/ZA965750B/xx
Priority to AU65233/96A priority patent/AU6523396A/en
Priority to PCT/FR1996/001071 priority patent/WO1997003047A1/fr
Priority to CA002224411A priority patent/CA2224411A1/fr
Priority to JP9505563A priority patent/JPH11508911A/ja
Priority to EP96924961A priority patent/EP0842150A1/fr
Publication of FR2736638A1 publication Critical patent/FR2736638A1/fr
Application granted granted Critical
Publication of FR2736638B1 publication Critical patent/FR2736638B1/fr
Priority to US09/005,154 priority patent/US5889053A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
FR9508423A 1995-07-12 1995-07-12 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent Expired - Fee Related FR2736638B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR9508423A FR2736638B1 (fr) 1995-07-12 1995-07-12 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
ZA965750A ZA965750B (en) 1995-07-12 1996-07-05 Farnesyl transferase inhibitors their preparation and pharmaceutical composition comprising them
PCT/FR1996/001071 WO1997003047A1 (fr) 1995-07-12 1996-07-10 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
CA002224411A CA2224411A1 (fr) 1995-07-12 1996-07-10 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
AU65233/96A AU6523396A (en) 1995-07-12 1996-07-10 Novel farnesyl transferase inhibitors, preparation thereof and pharmaceutical compositions containing said inhibitors
JP9505563A JPH11508911A (ja) 1995-07-12 1996-07-10 新規ファルネシルトランスフェラーゼ阻害剤、それらの製造および該阻害剤を含む医薬組成物
EP96924961A EP0842150A1 (fr) 1995-07-12 1996-07-10 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US09/005,154 US5889053A (en) 1995-07-12 1998-01-09 Farnesyl transferase inhibitors, preparation thereof and pharmaceuticals compositions containing said inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9508423A FR2736638B1 (fr) 1995-07-12 1995-07-12 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
FR2736638A1 FR2736638A1 (fr) 1997-01-17
FR2736638B1 true FR2736638B1 (fr) 1997-08-22

Family

ID=9480919

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9508423A Expired - Fee Related FR2736638B1 (fr) 1995-07-12 1995-07-12 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent

Country Status (8)

Country Link
US (1) US5889053A (fr)
EP (1) EP0842150A1 (fr)
JP (1) JPH11508911A (fr)
AU (1) AU6523396A (fr)
CA (1) CA2224411A1 (fr)
FR (1) FR2736638B1 (fr)
WO (1) WO1997003047A1 (fr)
ZA (1) ZA965750B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780974B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
WO2006123182A2 (fr) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulfones de cyclohexyle pour le traitement du cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (fr) 2006-09-22 2008-04-03 Merck & Co., Inc. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
BRPI0812159A2 (pt) 2007-05-21 2017-05-02 Novartis Ag inibidores de csf-1r, composições e métodos de uso
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
EP2413932A4 (fr) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibiteurs de l'activité akt
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
CA2784807C (fr) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
BR112012023021A2 (pt) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
WO2012016021A2 (fr) 2010-07-28 2012-02-02 Veridex, Llc Procédés de détermination de réponse de la leucémie myéloïde aiguë à traitement par inhibiteurs de la farnésyltransférase
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
EP2608669B1 (fr) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
WO2013074986A1 (fr) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-n-terminale (jnk)
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063054A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2951180B1 (fr) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
WO2015058126A1 (fr) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Composés hétéroaromatiques utiles dans le traitement de maladies prolifératives
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016160617A2 (fr) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
EP3307728A4 (fr) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
HUE057306T2 (hu) 2015-08-17 2022-04-28 Kura Oncology Inc Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
EP3347018B1 (fr) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EA201991091A1 (ru) 2016-11-03 2019-11-29 Способы лечения пациентов со злокачественными новообразованиями с применением ингибиторов фарнезилтрансферазы
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2019113269A1 (fr) 2017-12-08 2019-06-13 Kura Oncology, Inc. Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
WO2019148412A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044333A1 (fr) * 1990-06-12 1991-12-13 Jackson B. Gibbs Agents chimiotherapeutiques
US5504212A (en) * 1992-10-29 1996-04-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5705686A (en) * 1993-05-18 1998-01-06 University Of Pittsburgh Inhibition of farnesyl transferase

Also Published As

Publication number Publication date
CA2224411A1 (fr) 1997-01-30
AU6523396A (en) 1997-02-10
EP0842150A1 (fr) 1998-05-20
WO1997003047A1 (fr) 1997-01-30
ZA965750B (en) 1997-01-27
US5889053A (en) 1999-03-30
FR2736638A1 (fr) 1997-01-17
JPH11508911A (ja) 1999-08-03

Similar Documents

Publication Publication Date Title
FR2736641B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730491B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2736638B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730492B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2742751B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2727411B1 (fr) Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent
DZ2009A1 (fr) Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2676446B1 (fr) Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2683531B1 (fr) Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
ZA96258B (en) New farnesyl tranferase inhibitors their preparation and the pharmaceutical compositions which contain them
FR2642069B1 (fr) Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2732968B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2779724B1 (fr) Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757166B1 (fr) Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2687151B1 (fr) Nouveaux derives de la baccatine iii et de la desacetyl-10 baccatine iii, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2745814B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2732342B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2712288B1 (fr) Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2712289B1 (fr) Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2721021B1 (fr) Nouveaux inhibiteurs de farnésyl transférase, leur préparation et les compositions pharmaceutique qui les contiennent.
FR2705094B1 (fr) Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2705097B1 (fr) Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2721023B1 (fr) Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2757855B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2733498B1 (fr) Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
ST Notification of lapse